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Abstract
Background: Hepatocellular Carcinoma (HCC) is one of the commonest cancers in Central Africa, a region with the
unusual peculiarity to be hyperendemic for infections with Hepatitis B, C and D viruses. However, data estimating
the respective proportions of HCC cases attributable to these viruses are still limited in this area. The current study
was undertaken to determine the role of these viruses in HCC compared to non-HCC Cameroonian patients.
Methods: A case–control study was conducted in the Gastroenterology Unit of Central Hospital of Yaounde in
collaboration with Centre Pasteur of Cameroon. Blood samples of all HCC cases (n = 88) and matched control
individuals without known liver disease (n = 85) were tested for serological markers of Hepatitis B, C and D viral
infections using commercially available enzyme immune-assay kits. Hepatitis B and C viral loads were quantified for
positive patients by real-time PCR using commercial kits.
Results: The mean age was 46.0 ± 18 and 42.1 ± 16 years old for HCC-patients and controls, respectively for a 2.3
Male/Female sex ratio. The prevalence of hepatitis B surface antigen, antibody to HCV and antibody to HDV were
significantly higher in HCC patients (65.90, 20.26 and 26 % respectively) than in control patients (9.23, 4.62 and 1 %)
(P < 2.5 10−5). The risk factors analysis showed that both HBV and HCV infections were strongly associated with HCC
development in Cameroon with crude odds ratios of 15.98 (95 % CI 6.19-41.25) and 7.33 (95 % CI 2.09-25.77),
respectively. Furthermore, the risk of developing HCC increased even more significantly in case of HBV and HDV co-
infections with the odd ratio of 29.3 (95 % CI, 4.1-1231). HBV-DNA level was significantly higher in HBsAg-positive
HCC-patients than in HBsAg-positive controls with (6.3 Log IU/mL and 5.7 Log IU/mL) respectively (P < 0.05).
Conclusion: HBV and HCV infections are the mains factors of HCC development in Cameroon. Our results show
that patients co-infected with HDV are at very high risk to develop HCC. An active surveillance program of patients
and, foremost, an easier access to antivirals and primary prevention measures are crucial steps to reduce the
incidence of HCC in this country. Due to the lack of truly efficient antiviral therapy, the fate of HDV-infected patients
remains, however, particularly worrying.
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Background
Hepatocellular carcinoma (HCC) is the second most
common cause of cancer death in the world and is
particularly prevalent in Africa and Asia [1–3]. There
is a strong correlation between the incidence of HCC
and the prevalence of chronic hepatitis B and C, indi-
cating that these two viral infections are some of the
most important risk factors of HCC worldwide with a
combined attributable fraction of at least 75 % of all
HCC cases [4, 5].
Growing evidence indicates that the high incidence
areas of HCC correspond primarily to the zones where
chronic hepatitis B is prevalent and exposure to aflatoxin
B1 (AFB1), a mutagenic mycotoxin, is frequent [6]. In
addition to viral hepatitis infections and dietary AFB1
exposure many other risk factors associated with HCC
are well documented. They include heavy alcohol con-
sumption, iron overload, type II diabetes and cigarette
smoking [6].
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In Cameroon, HCC has been reported as the country’s
commonest type of cancer [7]. Cameroon, as other
countries of Central Africa (eg Burundi) is also a hyper-
endemic area for hepatitis B, C and D viral infections with
HBsAg prevalence ranging between 6 and 33 % [8–11],
anti-HCV between 4 and 30 % [11, 12] and anti-HDV be-
tween 13 and 62.5 % of HBV surface antigen (HBsAg)
carriers [13] depending on the population and the area
studied.
However, like for other developing countries in
Central Africa, recent and first-hand data regarding the
involvement of hepatitis B and C viruses in HCC is ra-
ther limited [14]. The few available studies carried out in
Cameroon bring out essentially the clinical, epidemio-
logical and diagnostic aspects of HCC resulting from
cross sectional analyses [15, 16]. So far, information on
the respective involvement of HBV and HCV in HCC re-
mains unknown. The current study was undertaken to
assess the risk associated with the three viruses in HCC-
cases compared to HCC-control (non-hepatic disease)
Cameroonian patients using a case–control study.
Methods
Patients
A case–control study was performed. Cases were made
of HCC patients consecutively enrolled in the Gastro-
enterology and Radiology Units of Central Hospital,
Yaoundé between February 2013 and January 2014. They
were individually 1:1 paired-matched by sex and age
(±5 years) with control subjects consecutively selected
and represented by patients without clinical symptom of
liver diseases attending at the same period the same
medical departments.
The diagnosis of HCC was based on presence of a liver
mass at ultrasound and, when possible, histology of tis-
sues samples together with elevation of serum alpha-
fetoprotein (AFP) (>400 ng/ml) levels. Of the 88 HCC
cases included, 61 % (n = 54) were found with AFP levels
of 400 ng/mL or higher, 20.5 % (n = 18) had AFP level
less than 400 ng/mL or above normal values (>16.5 ng/
mL). In the remaining cases (n = 16) AFP were found
normal (<16.5 ng/mL). Inclusion criteria for control sub-
jects without clinical evidence of liver disease were the
absence of previously known hepatitis, the presence of
normal level of serum AFP (<16.5 ng/ml) and no liver
mass at ultrasound examination. Written informed con-
sent was obtained from all the patients (or from parents,
in the case of children). The study protocol conformed
to the ethical guidelines of the 1975 declaration of
Helsinki was approved by the National Ethics Commit-
tee and the Ministry of Health of Cameroon. All the
cases and controls were interviewed using a standard
questionnaire that gathered information on demographic
characteristics, past medical history, family history of
liver disease, history of alcohol drinking, cigarette smok-
ing, dietary history and history of blood transfusion. All
the blood samples collected were aliquoted and stored at
−80 °C until analyzed.
Serological tests
HCV serology
The presence of antibodies against HCV (anti-HCV)
was checked by the use of a third-generation enzyme
immunoassay (EIA, Monolisa anti-HCV Plus version 2;
Bio-Rad, Marne-La-Coquette, France). The reactivity of
samples was determined as described by Njouom in
2003 [17]. Briefly, a ratio was calculated for each sample
by dividing its optical density by the cut-off value. A
positive result for anti-HCV was defined as a Monolisa
ratio greater than 6 whereas all samples with a <6 ratio
were scored as negative.
HBV serology
Different serological markers of HBV were assessed
using commercial kits: hepatitis B surface antigen
(HBsAg) antibody to hepatitis B core antigen (Anti-
HBc), antibody to HBsAg (anti-HBs) and hepatitis e
antigen (HBeAg). The presence of HBsAg was tested by
enzyme-linked immunosorbent assay (ELISA) by the use
of third generation reagents (Murex AgHBs version 3;
DiaSorin, SPA UK BRANCH) and the presence of ant-
HBc andanti-HBs were detected by enzyme immuno-
assay (EIA) by the using the respective commercial kits
of (Monolisa; Bio-Rad, Marne-La-Coquette, France).
Participants positive for HBsAg were tested for HBV “e”
antigen (HBeAg) as a surrogate marker of active replica-
tion using enzyme immunoassay kit (Monolisa, Bio-Rad,
Marne-La-Coquette, France). All the reactivity was de-
termined according to the manufacturer’s instructions.
Infection with HBV was defined positive when only
HBsAg was detected or both HBsAg and HBeAg in the
same patient.
HDV serology
The presence of antibodies against HDV (anti-HDV)
was assessed only in HBV positive patients using com-
mercial kits for enzyme-linked immunosorbent assay
(ELISA) by the use of ETI-AB- DELTAK-2 Anti-HDV;
DiaSorin, P2808). The reactivity of samples was deter-
mined according to the manufacturer instructions. .
Samples with absorbance values within +/−10 % of cut-
off value were retested in order to confirm the initial re-
sult. Only repeatedly reactive samples were considered
positive.
Molecular analysis
Occult hepatitis B characterized by the presence of
hepatitis B virus (HBV) DNA in the serum of patients in
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the absence of serological markers signing active viral
replication was identify in this study [18, 19] by quantifi-
cation of HBV viral loads in HCC-cases negative for
HBsAg. In addition we also searched for HCV RNA and
quantified HCV viral loads in patients with anti-HCV
antibodies to search for possible HCV occult infection.
Plasma HCV-RNA and HBV-DNA levels were quantified
using Abbott RealTime assay (Abbott Molecular Inc,
Des Plaines, IL 60018 USA) according to manufacturer’s
instructions. The lower detection limit of the assay for
HCV infection was defined as viral load value greater
than 12 viral RNA copies ml−1 (IU/mL). For HBV infec-
tion, the limit of the assay was defined as viral load value
greater than 10 viral DNA copies ml−1(IU/mL).
Statistical analyses
Data were presented as mean ± SD. Prevalence of HBV
and HCV were compared between HCC-cases and
HCC-controls. The odds ratios (ORs) were calculated to
assess the risk of HCC using a conditional logistic re-
gression analysis and confidence interval were deter-
mined. Viral loads were compared using T test or
Mann–Whitney U test as appropriate following log2
transformation of the values. . The difference was consid-
ered statistically significant for P < 0.05. The analysis was
performed using SPSS 16.0 and Prism 6.0 (GraphPad Inc,
La Jolla, CA, USA) statistical softwares.
Results
Baseline characteristics
In all, 88 HCC-cases and 85 controls were included in
this study. The mean age of HCC-cases was 46.0 ±
18.8 years (age range 8–93 years). Among the HCC-
cases, 69.3 % (61/88) were men (45.8 ± 18.8 years) and
30.7 % (27/88) were women (46.5 ± 19.1 years). For the
85 controls included, 21 had diseases that need to be
treated in the division of cardiology, 52 in internal medi-
cine and 12 in the division of surgery. Every control pa-
tients was definitely diagnosed without clinical symptom
of liver disease and without HCC. The mean age of the
controls was 42.1 ± 16.4 years (age range: 11–82 years).
Among these, 67.1 % (57/85) were men with the mean
age of 41.9 ± 15.1 and 32.9 % (28/85) were women with
the mean age 46.5 ± 19.1 years. The mean age between
HCC-cases and controls was not significantly different.
The basic demographic characteristics of patients are
shown in Table 1.
Serological prevalence of hepatitis viruses markers in HCC
patients and controls
The prevalence of HBV, HCV and HDV markers is
shown in Table 2. Hepatitis B surface antigen (HBsAg)
was present in 65.9 % (58/88) of the cases and in 10.6 %
(9/85) of the controls. The difference between the two
groups was significantly different (P < 0.0001). The pres-
ence of Anti-HBc positivity was found more prevalent in
HCC patients than in controls patients with 82.9 and
78.8 % respectively (NS). The presence of both Anti-
HBc and Anti-HBs defined as resolutive HBV was
significantly (P < 0.05) present in controls patients com-
pared with HCC-cases with 45.1 % vs 12.5 % respect-
ively. Of the 58 HBsAg positive HCC-cases found,
hepatitis Delta antibody (Anti-HDV) co-infection was
present in 41.4 % (24/58). Only one control was co-
infected with HDV infection in our study. Regarding
HCV infection, the antibody against HCV (Anti-HCV)
was also more frequently detected in HCC-cases com-
pared to the controls (26.1 % (23/88) vs 3.5 % (3/85) re-
spectively). The difference between the two groups was
significantly different (P < 0.0001). Overall, the preva-
lence the serological markers for the three viruses were
much higher in HCC-cases than in controls patients.
Only 16 % of HCC cases (n = 14) were free from markers
of chronic hepatitis whereas this proportion was 87 % in
controls (P < 0.0001). Taken together, the OR associated
with positivity for either HBsAg or anti-HCV was 35
(95%CI: 15.0-81.9).
Dual HBV and HCV infection was observed in 5.7 %
(5/88) of HCC-cases and in 1.2 % (1/85) of control and
triple infection was only found in one HCC patient
(2.3 %).
A small subset of patients was positive for HBV early
antigen (HBeAg). These patients were much younger
than the whole series (mean = 29.4 years, Range 21–36).
No controls were presenting a positive serology for
HBeAg. Due to the small number of positive subjects,
the difference between cases and controls was, however,
not reaching the degree of statistical significance (P =
0.059, OR = 11.2, 95%CI = 0.6-207.1).
Table 1 Demographic characteristics of patients with HCC and
controls
Characteristics HCC cases (N = 88) Controls (N = 85)
Sex
Male 61 (69.32 %) 59 (69.4 %)
Female 27 (30.68 %) 26 (30.6 %)
Age (Years)
Mean age 46.01 ± 18.81 42.11 ± 16.40
Age range 8–93 11–82
Age groups
< 20 5 5
20–39 36 36
40–59 22 22
≥ 60 25 22
HCC hepatocellular carcinoma
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Hepatitis B and C viral loads in HCC patients and controls
As shown in Table 3, HBV and HCV genomes were re-
spectively found in 93 % (54/58) and 87 % (20/23) of
serologically positive HCC-cases and in 67 % (6/9) and
100 % (3/3) of the corresponding controls. HBV-DNA
level were significantly higher in HBsAg-positive HCC-
cases than in HBsAg-positive controls with (6.3 Log UI/
mL and 5.7 Log UI/mL) respectively (P < 0.05). HCV-
RNA levels were also higher in anti-HCV positive HCC-
cases (5.5 log10) than in anti-HCV positive controls (5.2
Log 10) although the difference was not statiscally
significant.
We further analyzed viral loads in HCC-HBV related
co-infected with hepatitis Delta virus infection compared
to those without HDV infection. The mean of HBV viral
load were significantly low in patients co-infected with
HDV compared with patients without HDV infection.
HBV DNA loads were decreased in HDV-positive sam-
ples when compared with HBsAg (+) only (3.6 ± 1.7 vs
4.5 ± 2.1) but the difference was not statistically signifi-
cant (P = 0.13).
Regarding occult hepatitis, 30.0 % (9/30) of HBsAg (−)
patients were found positive by PCR suggesting a high
rate of occult B infection (OBI) in HCC-cases in this co-
hort. The mean age of the 9 OBI identified was signifi-
cantly higher than the mean age of patients with overt
infection (59.9 ± 14.1 vs 39.04 ± 14.7 years) respectively
suggesting that the kinetics of the tumor development
can differ between overt and occult HBV infection. The
overall proportion of patients with overt or occult B in-
fection was thus reaching 76 % (n = 67/88). By contrast,
no HCC case was occult for HCV in this study.
Analysis of HBV, HCV and HDV as risk factors for HCC
The analysis of serological markers as risk factors con-
firmed that the risk of developing HCC was strongly as-
sociated with the three viruses in our country. The odds
ratios (OR) and 95 % confidence interval (CI) for pres-
ence of HBV, HCV and HDV markers were 16.3 (7.2-
37.1), 9.6 (2.8-33.6) and 29.3 (4.1-1231) respectively.
Similarly, the adjusted OR with sex and age values for
each infection was very high (Table 2) suggesting that, in
Central Africa, the carcinogenic risk associated with
HBsAg positivity is higher than the risk associated with
anti-HCV sero-reactivity (Table 2). The strongest hepa-
tocarcinogenic viral factor in Cameroonian patients was,
however, the presence of an infection with HDV.
In order to characterize a possible stratification of the
viral markers within the series examined, the association
between viral hepatitis, age range and sex was also ana-
lyzed. The sex ratios of HBV, HDV and HCV positive
cases were not significantly different (P > 0.05). By the
contrast, the age distribution was significantly different
(P < 0.05) among anti-HCV positive patients and HBsAg
positive patients (64.6 ± 15.5 years vs 39.04 ± 14.7 years).
The same observation was also found in patients co-
Table 2 HBV, HCV and HDV infection in HCC patients and controls and estimates of HCC risk
Hepatitis markers Controls HCC cases Unadjusted HCC risk Adjusted HCC risks
No % No % OR (95 % CI) OR (95 % CI)
HBV status
HBsAg positive 9 10.6 58 65.9 16.3 7.2-37.1 141.7 11.5-1747.6
HBeAg positive 1 11.1 5 8.6 11.2 0.6-207.3 38.79 4.04-305.2
Anti-HBc positive 67 78.8 73 82.9 1.31 0.6-28 0.68 0.03-16.7
Anti-HBs positive 59 69.4 23 26.1 0.16 0.8-3.2 0.56 0.018-15.1
HCV status
Anti-HCV positive 3 3.5 23 26.1 9.7 2.7-33.6 51.9 3.8-711.03
HDV status
Anti-HDV positive HBV-related 1 11.1 24 41.1 5.72 0.75-39.27. 5.65 0.66-48.16
Anti-HDV positive 1 1.17 24 27.27 29.3 4.1-1231 35.65 3.66-682.16
Note: Adjusted analysis represents multivariable model including age gender. Abbreviations: HCC hepatocellular carcinoma, HBV hepatitis B virus, HCV hepatitis C
virus, HBsAg hepatitis B surface antigen, Anti-HBc antibody against hepatitis B core antigen, Anti-HBs antibody against hepatitis B surface antigen, Anti-HCV
antibody against hepatitis C virus, Anti-HDV antibody against hepatitis D virus, CI Confidence intervals, OR Odds Ratio
Table 3 Molecular analysis of HBV and HCV infections in HCC patients and controls
Variables Controls HCC cases
No % Mean (log10 IU/ml) No % Mean (log10 IU/ml)
HBV viral load 6 67 5.7 54 93 6.3
HCV viral load 3 100 5.2 20 87 5.7
HBV hepatitis B virus, HCV hepatitis C virus
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infected with HDV infection. The peak of incidence of
HBsAg and anti-HDV were located in the 20–39 years
old subset and about 80 % of HCV-related HCC patients
were in the age group ≥60 years. The liver tumor devel-
opment process appears, therefore, as drastically differ-
ent between both viruses in Cameroon, a situation
plausibly due to the usual significant difference of age at
contamination. The age distribution of the subjects ana-
lyzed is shown in Fig. 1a,b and c.
Discussion
This is the first reported case–control study of HCC in
Cameroon and to the best of our knowledge the first in
Central Africa (Cameroon, Central African Republic,
Chad, Gabon, Congo, Democratic Republic of Congo)
an ensemble that counts 136 million inhabitants.
A close relationship between the development of HCC
and older age in the settings of HBV or HCV infections
has been stressed in various areas of the world [20–24].
El-Serag et al. [20]. In the current work, we observed
an overall low mean age of patients (46 years) when
compared to the situation prevailing in resource-rich
countries where the tumor mostly occurs at an age that
ranges from the late fifties to the early seventies (ap-
proximate mean age 65 years) [21–25] . Our data are,
however, similar to that reported in previous studies
conducted on Cameroonian HCC cases and to other
studies conducted in Central Africa countries like Gabon
[26]. Our finding are also in accordance with some stud-
ies conducted in West Africa countries like Nigeria [27],
Gambia [28] and Ghana [29]. Our results contrast how-
ever, with those of North Africa HCC patient [23]. It
seems thus, that the kinetics of tumor development is
stable since decades and homogeneous throughout Sub
Saharan Africa.
The high male-to-female ratio (2.3) observed in this
Cameroonian cohort of HCC cases is similar to those re-
ported from the East (2.4), the West (2.2) and the South
(2.3) of Africa [14] and in the literature. This may be
due in part from higher prevalence of HBV and HCV in-
fections among men and/or to the fact that males usu-
ally have history of drinking alcohol [30–33] .
In the present study, all three viruses responsible for
chronic hepatitis were strongly associated with HCC de-
velopment in Cameroon. Our results show that HBV is
the predominant risk factor associated with HCC devel-
opment in our country; as we found, it is involved in
65 % of cases with overt infection and in 75 % of cases
when both overt and occult B infections were regrouped.
Furthermore, almost all of our patients had a serological
marker of previous HBV infection. The high prevalence
of HBV infection was consistently reported in various
groups of patients in Cameroon: 10.1 % in blood donors
[12], 20.4 % in pregnant women [10], 23.6 % in health
care workers [11] and 33 % in the Bantus enrolled in
Central, South, North West and East part of the country
[13]. Our findings regarding HBV prevalence in HCC is
in keeping with data reported for decades in Gabon
(40.5 %) and many studies conducted in West African
countries like Niger (73 %), Senegal and Mali (63 %),
Gambia (60 %) and Nigeria 61 % [26, 34–36]. This ob-
servation confirms that HBV infection is still the most
important risk factor of HCC development in Sub
Saharan Africa and that Central Africa does not differ
from other sub Saharan regions.
We observed the presence of Anti-HCV in 26 % of the
HCC-cases. Similar levels were found in different studies
conducted in Sub-Saharan Africa [34, 36]. Our results
contrast, however, with those of the study conducted in
2008 by Perret et al. on hepatitis B and C chronics
patients from Gabon where the prevalence of the two vi-
ruses were equal and many study conducted in HCC-
cases of the North of Africa were it is HCV infection
which is generally more prevalent. In Cameroon, as in
many other countries, anti-HCV carriers represent a
birth cohort (>50 years old) for which the disease-
associated burden will progressively decreases as this
generation will pass away.
Much less is known about HDV in Sub-Saharan
Africa. In this study, a high proportion of patients co-
infected with Hepatitis Delta virus was also detected in
HCC cases (41.1 %) compared to control individuals
(1.1 %). The present result is consistent with previous
studies conducted on non HCC patients with liver dis-
eases in Cameroon [9, 13], in many Sub-Saharan coun-
tries and the literature [29]. By contrast, our findings
were markedly different from that reported in Nigerian
HCC cases [37] where it was reported no HDV co-
infection both in HCC cases and controls.
The impact of active replication is known to be associ-
ated with an increased risk of HCC development [38, 39].
In the present work, the mean of HBV and HCV viral
loads were significantly high in HCC patients compared to
control patients. Regarding patients co-infected with
HDV, the means of HBV viral load were significantly low
in patients co-infected with HDV compared with patients
without HDV infection (15328.4 IU/ml vs 261264.1 IU/
ml) respectively. This result indicates as reported by previ-
ous studies the inhibition of HBV replication in HDV in-
fection [9, 40]. We observed above 16-fold, 10-fold and
29-fold odds ratios increase for HCC risk in HBV, HCV
and HDV infections respectively. Our data indicate that
HBV and HCV infections are involved in the vast majority
of HCC-cases observed in Cameroon. We detected at least
one viral marker in around 85 % of cases. This result indi-
cates that most Cameroonians HCC cases are resulting
from a hepatotropic virus-related chronic liver disease.
Similarly to what was reported in Cameroon and
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Fig. 1 a Age range distribution of hepatitis surface antigen (HBsAg) in HCC cases and controls; b Age range distribution of antibody against
hepatitis C virus (Anti-HCV) in HCC cases and controls, and (c): Age range distribution of antibody against hepatitis D virus (Anti-HDV) in HCC
cases and controls
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elsewhere, we observed that tumor onset is drastically dif-
ferent (25 years apart) between HBV- and HCV-infected
patients. This observation suggests either that it takes lon-
ger to HCV to result in a HCC or that HCV infection
occuring later in life (through contact with inappropriate
health practices for example) as compared to vertical or
early horizontal HBV transmission, kinetics of both
tumorigenic processes are grossly similar. Overall, both
vertical transmission and early horizontal infection for
HBV [41, 42] coupled to parenteral exposition in the
1980s for HCV [43–46] explain the spread of both viruses
in Cameroon and provide the epidemiological bases of
liver tumor development.
In this study, approximately 15 % of the HCC patients
were negative for HBV and HCV markers. Our finding
suggests that there is thus a significant involvement of
non-viral factors in the incidence of HCC development
in Cameroon. In many African and Asian countries,
HCC has been associated with chronic exposure to Afla-
toxin B1, a mycotoxin known to be present in Cameroon
staple-food such as maize [47]. There are some limita-
tions in this study that should be considered. First, we
used only anti-Delta Ab to validate the association be-
tween HDV infection and HCC; second, HBV DNA and
HCV RNA were not searched in negatives HBV and
HCV controls. Molecular analysis will better assess the
interplay between HDV infection and estimate the real
implication of HBV and HCV infections in the develop-
ment of HCC.
Beside environment, lifestyle risk factors, including
prolonged abuse of alcohol or cigarette smoking, both
highly prevalent in Cameroon, are known to increase
liver cancer risk [1, 5]. All these factors were not evalu-
ated in this study and their contributory role as causative
agents of HCC in Cameroon is still poorly documented.
There is therefore an urgent need for further studies
aiming to evaluate their possible involvement of non-
viral co-carcinogenic factors acting alone or in associ-
ation with the viruses on HCC development.
Conclusion
In summary, this study provides for the first time a land-
scape of the major viral risk factors associated with HCC
development in Cameroon and in Central Africa. Our
results show that patients co-infected with HDV or
mono-infected with HBV are at very high risk to develop
HCC. We consider that in absence of an easy access to
novel antiviral compounds, effective preventive measures
aiming to control HBV transmission (vaccination at
birth, better hygiene) are of paramount importance to
reduce the pool of Cameroonians citizens at risk and sig-
nificantly curb down the future HCC incidence in
Central Africa including Cameroon. Among all individ-
uals at risk, HDV-infected represent the most worrying
subpopulation due to the almost complete lack of effi-
cient antiviral compounds active on HDV and to the re-
markably high relative risk of HCC associated with this
viral infection. A national epidemiological survey aiming
to identify groups at risk to be HDV-infected and a
closer surveillance of hepatitis delta among women in
reproductive age should be undertaken now in
Cameroon.
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